Workshop 2014
Lessons learned in building HTPD capabilities
A workshop to discuss the benefits and pitfalls of establishing in-house HTPD workflows and equipment.
Intention of Workshop Content
The workshop included short presentations by scientists followed by a panel discussion. Topics included method development, industry benchmarking, HTPD successes and failures, what workflows were most and least appropriated to automate, and how HTPD predictions could fit with scale-up executions.
| 15.00 — 15.20 | Part I | Introduction by Ashley Hesslein, PhD Senior Scientist, Global Biological Development Bayer HealthCare |
| 15.20 — 16.10 | Part II | Short presentations by panelists |
| 16.10 — 18.00 | Part III | Open discussion between panelists and audience |
Panel
| Dean Harde Senior Scientist |
Biopharma Process Science Downstream Boeringer-Ingelheim, Vienna |
| William Holmes Sr. Research Scientist |
Virology and Purification Development Eli Lilly and Company |
| Paul McDonald Scientist |
Purification Development Genentech, San Francisco California |
| Jennifer Pollard Principal Scientist |
Process Development and Engineering Merck, Kenilworth New Jersey |
| David C. Smithson, Ph.D. Scientist |
Early Stage Pharmaceutical Development Genentech, San Francisco, California |